Results 151 to 160 of about 624 (180)

Mildronate: Mechanisms of action and prospects for correction of pathologic states

Pharmaceutical Chemistry Journal, 1995
The energy metabolism of fatty acids (FA) is attributed to their intramitochondrial [?,-oxidation. FA with number of carbon atoms less than 12 penetrate into mitochondria by a camitine-independent pathway. Carnitine-y-trimethylamino[3-hydroxybutyrate is needed for the oxidation of long-chain FA [1, 2].
Zh. V. Shutenko, D. V. Meirena, T. I. Kagan, N. I. S'yakste, I. Ya. Kalvin'sh   +4 more
openaire   +1 more source

[Absence of mutagenic and carcinogenic properties in Mildronate].

Voprosy onkologii, 1999
Mutagenic and carcinogenic properties of mildronate (3-[2.2.2.-trimethyl hydrazonium]-propionate) have been studied for its marked immuno-stimulating and anti-ischemic action. When dosage up to 1,000 mg/dish was used no reversal of base-pair substitution or frame shift in S.typhimurium was observed. In drosophila females treated with mildronate, mosaic
G A, Belitskiĭ, I Ia, Kalvinysh, V N, Anisimov, E M, Khovanova, E G, Ugvinenko, Iu D, Tolcheev   +5 more
openaire   +1 more source

Dehydration of mildronate dihydrate: a study of structural transformations and kinetics

CrystEngComm, 2014
The dehydration of mildronate dihydrate (3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propionate dihydrate) was investigated by powder X-ray diffraction, thermal analysis, hot-stage microscopy, water sorption–desorption studies and dehydration kinetic studies.
Agris Bērziņš, Andris Actiņš
openaire   +1 more source

[Anti-atherosclerotic action of mildronate in experiment].

Patologicheskaia fiziologiia i eksperimental'naia terapiia, 2002
Mildronate is a new antiischemic drug which inhibits biosynthesis of carnitine from butyrobetaine. We studied antiatherosclerotic and antiinflammatory effects of mildronate in guinea-pigs, rats and rabbits. We found a hypolipidemic action of this substance in rats with triton WR-1339 hyperlipidemia. A protective antiatherosclerotic effect of mildronate
I V, Okunevich, V E, Ryzhenkov
openaire   +1 more source

[Mildronate in the treatment of transitory ischemic attacks].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013
An aim of the present study was to evaluate the treatment efficacy of the antioxidant mildronate in patients with transitory ischemic attacks. We studied the dynamics of clinical status, psychometric data and indices of free-radical lipid oxidation in 40 patients. The improvement in the subjective state, memory and attention was seen in 24 patients.
M Iu, Maksimova, T N, Fedorova
openaire   +1 more source

Effects of ischemia-reperfusion and pretreatment with mildronate on rat liver mitochondrial function

Pharmacological Reports, 2009
Mildronate (3-(2,2,2-trimethylhydrazinium) propionate), which is mostly used in cardiological practice and is considered an anti-ischemic drug, was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation.
Trumbeckaitė, Sonata, Kinčius, Marius, Preidis, Andrius, Preidienė, Monika, Veikutis, Vincentas, Borutaitė, Vilmantė, Gulbinas, Antanas   +6 more
openaire   +3 more sources

[Efficacy and safety of mildronate in emergency medical care].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014
Detailed clinical data about patients who used emergency services during 2011 are presented. The main attention is focused on the state of patients with acute and chronic brain ischemia before and after treatment with mildronate. Mean age of patients with ischemic stroke and chronic brain ischemia was 63.4 and 57.7 years, respectively.
N M, Nevzorov, Yu N, Markevich
openaire   +1 more source

MILDRONATE

Drugs of the Future, 1989
J. Prous, J. Castañer
openaire   +1 more source

[Evaluation of effectiveness of treatment of cochleovestibular disorders with mildronate].

Vestnik otorinolaringologii, 1991
The results of mildronate treatment of 67 patients with acute (23 patients) and chronic (44 patients) cochleovestibular disorders of different origin are discussed. The efficacy was evaluated in terms of subjective reports and objective parameters. The therapy proved effective in 53 (79.1%) patients, out of which it was good in 30 (44.8%) patients and ...
L A, Luchikhin, T B, Pankova, M I, Kakymov   +2 more
openaire   +1 more source

Meldonium (Mildronate): A Performance‐Enhancing Drug?

Clinical Pharmacology in Drug Development, 2016
H Karl, Greenblatt, David J, Greenblatt
openaire   +2 more sources